|
August 12, 2024
|
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
|
August 12, 2024
|
Biora Therapeutics Announces Funding Agreement with Existing Investors
|
|
August 8, 2024
|
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
|
|
August 6, 2024
|
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
|
|
July 18, 2024
|
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
|
|
July 8, 2024
|
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
|
|
July 1, 2024
|
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
|
|
June 11, 2024
|
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
|
|
May 20, 2024
|
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
|
|
May 15, 2024
|
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|